Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Related Clinical Trial
Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy Avatrombopag Usage in NSAA Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Investigation of the Cylex® ImmuKnow® Assay Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Umbilical Cord Blood Transplantation From Unrelated Donors Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study Unrelated Umbilical Cord Blood (UBC)Transplantation New York Blood Center National Cord Blood Program Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation A Phase II Study of Umbilical Cord Blood Transplantation Transplants With Unlicensed Preserved Cord Blood Safety Study of Cord Blood Units for Stem Cell Transplants Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. Protection Against Benzene Toxicity Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders King’s Invasive Aspergillosis Study II Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy Aplastic Anemia Epidemiology: Incidence and Case-control Drug Etiology of Aplastic Anemia and Related Dyscrasias hATG+CsA vs hATG+CsA+Eltrombopag for SAA Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) Haploidentical Transplantation in Severe Aplastic Anemia A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia Stem Cell Factor Medication for Aplastic Anemia Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome Extended Dosing With Eltrombopag for Severe Aplastic Anemia Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Oral Manifestations of Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: Combination Therapy of Severe Aplastic Anemia Comparing Therapies for the Treatment of Severe Aplastic Anemia Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. Study of AMG531(Romiplostim) in Patients With Aplastic Anemia Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia Alemtuzumab and Rituximab in Aplastic Anemia Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA) Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Brief Title

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Official Title

A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy

Brief Summary

      This was an open label, non-randomized, phase II study of eltrombopag in combination with
      rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior
      ATG/ALG-based immunosuppressive therapy. The objective was to assess additive effects of
      eltorombopag on overall response rate (ORR) at 6 months (Week 26) of treatment with ATG/CsA.
      Subjects were assessed at least weekly for safety during the period from the start of ATG/CsA
      to 4 weeks after the start of administration of eltrombopag. After that, subjects had visits
      every 2 weeks until Week 26. Subjects in whom the treatment was assessed as effective at Week
      26 could continued treatment with eltrombopag after 6 months when clinically indicated at the
      discretion of the investigator. There were five follow-up visits: at discontinuation of the
      treatment of eltrombopag, and Weeks 1, 2, 3, 4 and 26 after treatment discontinuation. As
      this study was the first Japanese phase II study in which this product was administered in
      combination with ATG/CsA to subjects with naive moderate or more severe AA, the subject
      number of this study was determined to be 10 based on the feasibility survey.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

ORR at 6 Months: Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at Week 26

Secondary Outcome

 ORR at 3 Months

Condition

Aplastic Anemia

Intervention

Eltrombopag

Study Arms / Comparison Groups

 Eltrombopag+rabbit ATG/CsA arm
Description:  Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

10

Start Date

May 12, 2015

Completion Date

September 6, 2017

Primary Completion Date

July 5, 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Japanese subjects aged >=18 and <71 years at the time of informed consent. Note:
             subjects aged >=71 and <75 may be eligible when clinically indicated at the discretion
             of the investigator by mutual agreement with Novartis medical advisor.

          -  Diagnosed with moderate or more severe AA according to the diagnostic criteria of AA.
             The severity classification is: Stage I - Mild - Other than the stages below; Stage II
             - Moderate - At least two of the following conditions are met: Reticulocyte
             <60,000/microliter, Neutrophil <1,000/microliter, Platelet <50,000/microliter; Stage
             III - Moderately severe - At least two of the following conditions are met and regular
             red blood cell transfusion (a need for transfusion of >=2 units per month) is
             required: Reticulocyte <60,000/microliter, Neutrophil <1,000/microliter, Platelet
             <50,000/microliter; Stage IV - Severe - At least two of the following conditions are
             met: Reticulocyte <20,000/microliter, Neutrophil <500/microliter, Platelet
             <20,000/microliter; Stage V - Very severe - At least one of the following conditions
             is met in addition to neutrophil <200/microliter: Reticulocyte <20,000/microliter,
             Platelet <20,000/microliter.

          -  Subjects who are considered an indication for the treatment with rabbit ATG and CsA.

          -  Adequate baseline organ function defined by the following criteria: Alanine
             aminotransferase (ALT), aspartate aminotransferase (AST)<=3 × local upper limit of
             normal (ULN) Creatinine, total bilirubin, and alkaline phosphatase (ALP) <1.5 × local
             ULN (total bilirubin <2.5 × local ULN with Gilbert's Syndrome)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 or 1

          -  Subjects with QTcF<450 millisecond (msec) or QTcF<480 msec with branch block: QTc is
             QT interval corrected by Fridericia formula (QTcF), machine ,or manual overread. QTcF
             is based on single or averaged QTc value of triplicate ECG.

          -  Subjects are able to understand and comply with protocol requirements and
             instructions.

          -  Subjects have signed and dated informed consent.

          -  Subjects who meet one of the following conditions: Male subjects who have a female
             partner of childbearing potential must either have a prior vasectomy or agree to use
             an acceptable method of contraception from time of enrollment in the study until 16
             weeks after the last dose of eltrombopag (based upon the lifecycle of sperm). Female
             subjects of non-childbearing potential (who are physiologically unable to become
             pregnant) defined as: Premenopausal women with documented bilateral oophorectomy,
             bilateral tubal ligation, or hysterectomy; or postmenopausal women after at least 12
             months of natural amenorrhea [if uncertain, postmenopausal state should be confirmed
             by hematology result of follicle stimulating hormone (FSH) >40 milli-international
             units (mIU)/milliliter (mL) or estradiol <40 picogram (pg)/mL (<140 picomoles
             (pmol)/L)]. Female subjects of childbearing potential: Defined as those not meeting
             the definition of non-childbearing potential. Female subjects of childbearing
             potential must have a negative serum human chorionic gonadotropin (hCG) or urine
             pregnancy test within 7 days prior to the first dose of ATG/CsA. It is recommended
             that the pregnancy test should be performed as close as possible to the first dose of
             ATG/CsA. Female subjects with a positive pregnancy test must be excluded from the
             study. Subjects with a negative pregnancy test must use acceptable contraception
             including abstinence after the pregnancy test. Subjects must agree to use the
             acceptable contraception including abstinence from 14 days prior to the first dose of
             ATG/CsA until 28 days after the last dose of eltrombopag.

        Exclusion Criteria:

          -  Diagnosis of congenital AA (e.g. Fanconi anemia or Dyskeratosis congenital).

          -  Subjects who have a sibling donor with matched human leukocyte antigen (HLA) or who
             underwent hematopoietic stem cell transplantation (HSCT) previously. However, such
             subjects may be enrolled if HSCT is not indicated, or the subject does not want to
             undergo HSCT.

          -  Subjects with abnormal chromosome (monosomy 7 detected by fluorescence in situ
             hybridization (FISH), or other aberrations detected by G-band staining). Note:
             Subjects with abnormal chromosome which is not adopted into the clone definition of An
             International System for Human Cytogenetic Nomenclature (ISCN) may be enrolled after
             consulting with medical monitor.

          -  Previous ATG/ALG-based immunosuppressive therapy or steroid pulse therapy for AA.

          -  Treatment with CsA within 6 months before administration of ATG.

          -  Subjects with a paroxysmal nocturnal hemoglobinuria (PNH) clone size in granulocytes
             of >50% by flow cytometric analysis.

          -  Pre-existing cardiac disease (congestive heart failure New York Heart Association
             (NYHA) Grade II/III/IV), or arrhythmias known to involve the risk of thromboembolic
             events (e.g. atrial fibrillation)

          -  Past history of thromboembolic event (including anti-phospholipid antibody syndrome)
             and current use of anticoagulants.

          -  Subjects with past or current malignancy. Note : Subjects who have a history of
             completely resected malignant tumor and have been disease-free for 5 years are
             eligible.

          -  Subjects who test positive for hepatitis B surface (HBs) antigen, hepatitis C virus
             (HCV) antibody, or human immunodeficiency virus (HIV) antibody at screening.

          -  Infection not adequately responding to appropriate therapy.

          -  Subject with liver cirrhosis

          -  Subjects with any clinically significant severe cardiac, renal, or hepatic medical
             condition.

          -  Pregnant women (a positive serum or urine pregnancy test within 7 days prior to the
             first dose of ATG/CsA or lactating women) Note: Female subjects who are lactating are
             eligible to participate if they discontinue nursing prior to the first dose of ATG/CsA
             and refrain from nursing until 5 days after the completion of treatment with
             eltrombopag.

          -  Known hypersensitivity, intolerance or allergy to rabbit ATG, cyclosporine A,
             eltrombopag or any of their excipients.

          -  Current alcohol or drug abuse.

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) proceeding the first dose of ATG/CsA.

          -  Subjects who is not candidates for ATG.

          -  Subjects who is not candidates for CsA.

          -  History of treatment with eltrombopag, romiplostim or other thrombopoietin-receptor
             (TPO-R) agonists.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Novartis Pharmaceuticals, , 

Location Countries

Japan

Location Countries

Japan

Administrative Informations


NCT ID

NCT02404025

Organization ID

201793


Responsible Party

Sponsor

Study Sponsor

Novartis Pharmaceuticals


Study Sponsor

Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals


Verification Date

May 2019